Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Detailed description
This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.
Arms & interventions
Outcome measures
Primary
Best Overall Response (BOR)
Time frame: Through study completion, up to approximately 4.9 years
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Time frame: Up to approximately 4.9 years
Overall Survival (OS)
Time frame: Through study completion, up to approximately 4.9 years
Number of Participants with Adverse Events (AEs)
Time frame: Up to approximately 4.9 years
Number of Participants with Adverse Reactions (ARs)
Time frame: Up to approximately 4.9 years
Eligibility criteria
Study locations (3)
Holy Cross Health
Fort Lauderdale, Florida, 33308-4603
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43221
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
References
- Thomas M, Christopoulos P, Iams WT, Mazieres J, Cortot AB, Peled N, Minuti G, Smit EF, Audhuy F, Berghoff K, Eggleton SP, Fries F, Hildenbrand M, Liu P, Mahmoudpour SH, Menzel C, Oksen D. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan 21.(PubMed)